Precipio

PRPO

Medical - Diagnostics & Research · Healthcare

Price

$30.45

+1.02 (+3.47%)

Market Cap

$54.3M

Exchange

NASDAQ

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Good

Cash Flow

Weak

Stability

Good

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+52.2% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 1.1M (2021) → 1.6M (2025)

Winston Score History

The full picture

Precipio is a small healthcare company that runs a cancer diagnostics laboratory. It tests patient tissue and blood samples to help doctors figure out what type of cancer a patient has, so the right treatment can be chosen. The company serves hospitals, oncology clinics, and physician groups, mainly across the United States.

Precipio earns money by charging for each diagnostic test it performs, with payments coming from insurance companies, hospitals, and sometimes patients directly. It also sells a product called IV-Cell, a technology that improves how certain cancer cells are grown and analyzed in labs. The company is very small, with a market cap under $10 million, and it operates at a loss, meaning it spends more than it earns right now. The biggest risk it faces is running out of cash before it can grow its test volume enough to become profitable.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+24.2% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

-345.4% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$0/ year

↓ Declining (-100% vs prior year)

0.0% of revenue

Below sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

21.5%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$3M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Company generates more cash than it spends — no dilution risk from fundraising

Growth + cash flow

Precipio is a rare growth stock that's already generating positive cash flow while growing at 24%. The Winston Score doesn't fully credit this transition from "burner" to "earner."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

44.7%

Healthy — 44.7% gross margin

Profit after running costs

Operating Margin

-8.5%

Losing money on operations — -8.5%

Return on the money invested

ROCE

-8.5%

Weak — -8.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+33.5%

Fast-growing sales (+33.5% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

2.9%

Thin free cash flow (2.9%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.23

Conservative — low debt load (0.23)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial